Boehringer Ingelheim has been granted full marketing authorisation by the European Commission for its HIV protease inhibitor (PI), Aptivus (tipranavir).
The Court of Appeal in England has ruled that the National Institute for Health and Clinical Excellence (NICE) was insufficiently transparent when disclosing why it had decided to limit access to Alzheimer's drugs.
